Gold nanorods deliver a one-two to cancer; Antares Pharma submits methotrexate NDA;

Cancer

> Gold nanorods that assemble themselves respond to a light trigger and deliver drug and a blast of heat right to cancer cells in a two-for-one attack. Article

> Australian researchers have created a nanoparticle that could mean oral delivery of the cancer drug 5-fluorouracil (5-FU), getting treatment to the gut for colorectal cancer. Article

Rheumatoid arthritis

> Antares Pharma ($ATRS) has submitted an NDA to the FDA for Otrexup for the treatment of rheumatoid arthritis and psoriasis. Otrexup delivers methotrexate under the skin using Medi-Jet technology. Press release

Drug delivery systems

> Researchers from Northern Ireland are developing microneedle arrays from hydrogels. Abstract

> Teva Pharmaceutical Industries ($TEVA) has dropped $300 million plans for a warehouse and IT center in Philadelphia and is focusing its plans on drug delivery of older products. Article

> University of Houston researchers are developing a system to deliver lifesaving drugs and fluids on the battlefield after traumatic injury. Press release

Licensing and patent news

> Cosmo Pharmaceuticals has signed an agreement to develop oral extended-release versions of AIMM Therapeutics' monoclonal antibodies, using its MMX technology. Press release

> Aphios has received notification of allowance in the U.S. for a patent for its oral microsphere and nanosphere insulin-delivery systems. Press release

> Under the terms of an agreement with Titan Pharmaceuticals ($TTNP), Braeburn Pharmaceuticals has gained U.S. and Canadian rights to the investigational product Probuphine, a subdermal delivery system for buprenorphine in opioid dependence. Press release

And Finally… A microactuator that flexes like a finger could pump drugs. Article | Press release

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.